{"id":95754,"date":"2025-10-24T15:54:07","date_gmt":"2025-10-24T15:54:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/95754\/"},"modified":"2025-10-24T15:54:07","modified_gmt":"2025-10-24T15:54:07","slug":"im-stuck-in-the-gray-market-for-glp-1s","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/95754\/","title":{"rendered":"I\u2019m stuck in the gray market for GLP-1s"},"content":{"rendered":"

On Oct. 16, President Trump promised to slash the price<\/a> of brand-name GLP-1 drugs like Ozempic and Wegovy to $150 a month. Even after a top health official suggested price negotiations between drugmakers and the administration were ongoing, the announcement sent Novo Nordisk and Eli Lilly stocks tumbling<\/a>. For patients who\u2019ve been priced out, that number sounded like relief.<\/p>\n

I got three texts within an hour: \u201cDoes this mean we won\u2019t need the research suppliers anymore?\u201d \u201cCan we go back to real pharmacies?\u201d \u201cDr. Doth\u00e9e, is this real?\u201d That\u2019s what my friends call me.<\/p>\n

I\u2019m not a doctor \u2014 I\u2019m just the person everyone texts when the rules change again. Most of them aren\u2019t using compounding pharmacies anymore \u2014 those dried up when the Food and Drug Administration cracked down. Like me, they\u2019ve turned to research-grade peptides labeled \u201cnot for human consumption,\u201d shipped from overseas suppliers with no prescriptions, no oversight, and no guarantees. I\u2019ve been tracking FDA crackdowns, compounding pharmacy pivots, and gray market peptide suppliers for almost two years. And here\u2019s what I know: Trump\u2019s $150 plan can\u2019t help people like me.<\/p>\n

I use GLP-1s and related drugs in a way that is, without a doubt, a roll of the dice \u2014 and so far, the odds have been in my favor. I know it, and the friends who ask me for advice know it. (This essay, of course, doesn\u2019t amount to a STAT endorsement of what I\u2019m doing.) Nevertheless, these medications feel lifesaving to me. The restlessness that had driven me to darker places finally settled. Cravings dimmed. The constant mental noise \u2014 the reach for something, anything \u2014 stopped.<\/p>\n

I\u2019ve never really been prescribed GLP-1s. Not in the traditional sense, anyway. I don\u2019t have diabetes or obesity. I just wanted to feel better. To feel in control of my recovery from addiction (GLP-1s show considerable promise there<\/a>) and in control of my body.<\/p>\n

\t\t\t\"\"\t\t<\/p>\n

\t\t\t\t\"\"\/
\n\t\t\t\tSTAT Plus: The end of compounded GLP-1 copies leaves many patients in a \u2018lose-lose\u2019 position<\/a><\/p>\n

In 2024, a smaller telehealth startup offering compounded GLP-1s gave me what I wanted \u2014 no labs, no doctor\u2019s visit, no pharmacy. Just a quick phone consultation and a promise. Because of a shortage of brand-name drugs, it was legal. I live in Los Angeles, where you can get an IV drip between Pilates and Botox, so maybe I shouldn\u2019t have been surprised when a box of syringes and a vial of tirzepatide showed up a week later. But I was. The ease of it made the whole thing feel both thrilling and suspect. I\u2019d said I wanted to lose a few pounds. That was all it took.<\/p>\n

And it worked. For months, I felt steady in a way I hadn\u2019t since before methamphetamine nearly killed me \u2014 clearer, calmer, my body finally cooperating instead of working against me.<\/p>\n

Then the rules changed. After shortages of brand-name drugs were resolved<\/a>, the FDA cracked down on compounded semaglutide and tirzepatide<\/a> in early 2025, ordering pharmacies to stop making them by spring. My go-to telehealth company folded. Another started shipping mystery blends with MCT oil and vitamin B-12. Doses dropped. Formulas shifted. My refill disappeared.<\/p>\n

So I went looking elsewhere. A Reddit thread pointed me to the gray market: a compounding pharmacy still shipping despite new regulatory pressure. Overnight, the price tripled. They called it a \u201cnew blend,\u201d but it was the same formula \u2014 just wrapped in enough novelty to justify the markup. The kind of price gouging that thrives when loopholes begin to close.<\/p>\n

Once you go gray, it\u2019s not just about GLP-1s anymore \u2014 it\u2019s a sprawling marketplace of experimental treatments. It looks like midnight browser tabs and syringes lined up on my counter, order numbers in place of prescriptions. That\u2019s where I found peptides like ipamorelin, BPC-157, GHK-Cu<\/a> \u2014 short chains of amino acids marketed online to boost growth hormone, improve recovery, even repair tissue. Most aren\u2019t FDA-approved. Some come labeled \u201cnot for human consumption.\u201d<\/p>\n

But still, I use them. It feels like a type of care the system can\u2019t provide me \u2014 care I\u2019ve had to find for myself, even if it exists outside what doctors would recommend.<\/p>\n

The only way to access a lot of these peptides is through underground channels. That doesn\u2019t necessarily make them dangerous \u2014 but it does mean I\u2019m trusting my health to a supply chain that barely exists. Labels smudge. Dates blur. Dosing varies. I crowdsource advice from Reddit threads and Telegram chats full of strangers. I know how it sounds.<\/p>\n

Still, it feels good to be the one choosing the risk \u2014 especially after a long stretch of drug and alcohol dependency that burned my life to the ground. For years, I acted like I had agency. I didn\u2019t. Now, even when I\u2019m wrong, it feels like the decision is mine \u2014 and that difference matters.<\/p>\n

I found a research supplier selling freeze-dried retatrutide labeled \u201cnot for human consumption.\u201d I mixed the powder myself using bacteriostatic water I ordered from Amazon. The first injection stung badly because I hadn\u2019t ordered the right brand. But even the \u201cgood\u201d brand isn\u2019t safe anymore. There are counterfeits now: off-color labels, wrong date formatting, faded text. I wouldn\u2019t have known if strangers on Reddit hadn\u2019t taught me how to spot them.<\/p>\n

\t\t\t\"\"\t\t<\/p>\n

\t\t\t\t\"\"\/
\n\t\t\t\tSTAT Plus: Ozempic for addiction: How an elite rehab center is using GLP-1s to \u2018obliterate\u2019 all kinds of cravings<\/a><\/p>\n

That was my first hint at just how fragile this whole system is \u2014 how much depends on crowdsourced trust and trial-and-error. When it came time to calculate dosing, I turned to the same hive mind. Most of these anonymous biohackers had entire dosing protocols mapped out \u2014 color-coded charts, conversion calculators, detailed walkthroughs. The deeper I scrolled, the more it mimicked science \u2014 spreadsheets, acronyms, and conviction standing in for credentials. I tell myself I\u2019m different from the obsessive ones. Then I realize I\u2019m Googling peptide blends at 2 a.m., trying to figure out whether my ipamorelin is combined with CJC-1295, or if GHK-Cu comes mixed with ingredients I can\u2019t pronounce.<\/p>\n

The FDA has issued repeated warnings about these peptides<\/a>: contamination, dosage variability, companies making false claims. They\u2019re not wrong, but here\u2019s the thing: The alternatives either disappeared or became unaffordable overnight.<\/p>\n

Now, when I inject something, I know it\u2019s risky. But I also know what I want: more energy, less brain fog and noise, a body I can actually live in. Not a shell. Not a mask. Just something that helps me stay present in my own life. A life I fought hard to keep.<\/p>\n

Trump\u2019s $150 promise might eventually make Ozempic cheaper. But it won\u2019t make it available to everyone. Coverage limits remain. Under Health secretary Robert F. Kennedy Jr., the Centers for Medicare and Medicaid Services still bar weight-loss drugs from reimbursement for most patients. BMI cutoffs and risk profiles decide who gets a prescription. Those of us who want GLP-1s for metabolic balance or recovery support don\u2019t fit the criteria. Lower prices can\u2019t fix a locked door. If the White House succeeds, the gray market may shrink \u2014 but the unmet need won\u2019t.<\/p>\n

GLP-1s show promise in all sorts of arenas outside of weight loss: drug addiction, alcoholism<\/a>, gambling<\/a>. For those of us who live with these crushing problems, it seems too cruel to wait for the regulatory process to catch up.<\/p>\n

At the same time, the official GLP-1 market is consolidating. Axios reported Tuesday<\/a> that Eli Lilly is overtaking Novo Nordisk, with Zepbound projected to hit $18 billion in sales next year versus Wegovy\u2019s $16.5 billion. Big Pharma is winning the war for market share \u2014 but they\u2019re still losing patients to the underground. Because even as branded drugs become more available and potentially cheaper, the same coverage restrictions, BMI cutoffs, and off-label barriers remain. I know how quickly need can turn to obsession. That\u2019s why I keep trying to understand what drives it \u2014 in me and in the system.<\/p>\n

The solution can\u2019t be to shut the underground down. It has to be to make it safer \u2014 to expand access for responsible use of GLP-1s to support addiction recovery. Fund research into peptide safety. Create legal pathways for experimental treatments that are accessible to people like me.<\/p>\n

Because right now, many of us aren\u2019t choosing between safe and unsafe. We\u2019re choosing between unaffordable but regulated, and accessible but risky. Until the system meets patients where they already are \u2014 in the gray zones between official medicine and survival \u2014 many of us will keep reconstituting our own solutions, one vial at a time.<\/p>\n

Nick Doth\u00e9e is a writer in Los Angeles. His work has recently appeared in the Cut, HuffPost, the Washington Post, and the San Francisco Chronicle. He is currently at work on an addiction memoir.<\/p>\n","protected":false},"excerpt":{"rendered":"On Oct. 16, President Trump promised to slash the price of brand-name GLP-1 drugs like Ozempic and Wegovy…\n","protected":false},"author":2,"featured_media":95755,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[5301,163,85,46,482,7299,591],"class_list":{"0":"post-95754","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-addiction","9":"tag-health","10":"tag-il","11":"tag-israel","12":"tag-medication","13":"tag-pharmaceuticals","14":"tag-weight-loss"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/95754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=95754"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/95754\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/95755"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=95754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=95754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=95754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}